Goodwin recently advised Assembly Pharmaceuticals on its announced merger with Ventrus Biosciences. The new company, to be renamed Assembly Biosciences, Inc. and traded on the Nasdaq Capital Market under ticker “ASMB,” will focus on the development of treatment options and the potential cure for the hepatitis B virus. The transaction is subject to shareholder approval and is expected to close in July.
Assembly, a virology-focused biopharmaceutical company, was founded in 2012 and has operations in Indianapolis and San Francisco.
Ventrus, founded in 2005 and headquartered in New York, N.Y., is a development-stage pharmaceutical company focused on the development of gastrointestinal products.
More information about the transaction is available in the companies’ press release.